Desazadesmethyldesferrithiocin Analogues as Orally Effective Iron Chelators
作者:Raymond J. Bergeron、Jan Wiegand、William R. Weimar、J. R. Timothy Vinson、Jörg Bussenius、Guo Wei Yao、James S. McManis
DOI:10.1021/jm980340j
日期:1999.1.1
Further structure-activity studies of desferrithiocin analogues are carried out. (S)-desazadesmethyldesferrithiocin, 2-(2-hydroxyphenyl)-Delta(2)-thiazoline-4(S)-carboxylic acid, serves as the principal framework in the current paper. Desazadesmethyldesferrithiocin can be structurally altered with facility, and data are already available on its iron-clearing properties and toxicity parameters. Four different kinds of structural modifications of this framework are undertaken: introduction of hydroxy, carboxy, or methoxy groups on the aromatic ring; alteration of the thiazoline ring; increasing the distance between the ligand donor atoms; and benz-fusion of the aromatic rings. The structural modifications described are shown to have a tremendous imp act on both the iron clearance and toxicity profiles of the desazadesmethyldesferrithiocin molecule. All of the compounds are assessed in a bile-duct-cannulated rodent model to determine iron clearance efficiency. Ligands which demonstrate an efficiency of greater than 2% are carried forward to the iron-overloaded primate for iron-clearing measurements. Ligands with efficiencies greater than 3% in the primate are then evaluated in a formal toxicity study in rodents. On the basis of the results of the present work, 2-(2,4-dihydroxyphenyl)-Delta(2)-thiazoline-4(S)-carboxylic acid is a promising candidate for clinical evaluation.
Genetic diversity in Taro (Colocasia esculenta Schott, Araceae) in China: An ethnobotanical and genetic approach
作者:Xu Jianchu、Yang Yongping、Pu Yingdong、W. G. Ayad、P. B. Eyzaguirre
DOI:10.1007/bf02864543
日期:2001.1
DE615227
申请人:——
公开号:——
公开(公告)日:——
FLORVALL L.; STJERNSTROEM N. E., ACTA PHARM. SUEC., 1979, 16, NO 2, 81-88
作者:FLORVALL L.、 STJERNSTROEM N. E.
DOI:——
日期:——
Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 Mpro)